Capricor Therapeutics Inc (CAPR)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Capricor Therapeutics Inc chart...

About the Company

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has

CEO

Linda Marban

Exchange

NASDAQ

Website

https://capricor.com/

$25M

Total Revenue

73

Employees

$199M

Market Capitalization

-5.73

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CAPR News

Capricor Therapeutics, Inc. (4LN2.F)

3d ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see a ...

Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

4d ago, source:

As you might know, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) just kicked off its latest annual results with some ...

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

18d ago, source: Business Insider

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript

18d ago, source: Seeking Alpha

Good afternoon, ladies and gentlemen, and welcome to Capricor Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation ...

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

12d ago, source:

CAP-1002 is an investigational cell therapy which aims to slow disease progression through immunomodulatory, anti-inflammatory and anti-fibrotic actions with the goal of potentially improving the rate ...

Capricor Therapeutics Inc CAPR

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?

11d ago, source: Hosted on MSN

Shares of Capricor Therapeutics (CAPR) have gained 32.6% over the past four weeks to close the last trading session at $5.19, but there could still be a solid upside left in the stock if short-term ...

Capricor: Q4 Earnings Snapshot

18d ago, source: The Washington Post

SAN DIEGO — SAN DIEGO — Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $762,000 in its fourth quarter. The San Diego-based company said it had a loss of 2 cents per share.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

19d ago, source: Stockhouse

Capricor has entered into a partnership for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...